1. Home
  2. IONS vs CART Comparison

IONS vs CART Comparison

Compare IONS & CART Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ionis Pharmaceuticals Inc.

IONS

Ionis Pharmaceuticals Inc.

HOLD

Current Price

$77.82

Market Cap

11.9B

Sector

Health Care

ML Signal

HOLD

Logo Maplebear Inc.

CART

Maplebear Inc.

HOLD

Current Price

$40.04

Market Cap

10.0B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
IONS
CART
Founded
1989
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.9B
10.0B
IPO Year
1996
2023

Fundamental Metrics

Financial Performance
Metric
IONS
CART
Price
$77.82
$40.04
Analyst Decision
Strong Buy
Buy
Analyst Count
22
21
Target Price
$93.36
$52.24
AVG Volume (30 Days)
1.6M
3.9M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
21.71
1.27
EPS
N/A
0.57
Revenue
N/A
$3,742,000,000.00
Revenue This Year
N/A
$13.44
Revenue Next Year
$77.99
$9.71
P/E Ratio
N/A
$68.14
Revenue Growth
N/A
10.78
52 Week Low
$32.00
$32.73
52 Week High
$86.74
$53.50

Technical Indicators

Market Signals
Indicator
IONS
CART
Relative Strength Index (RSI) 61.30 47.47
Support Level $75.66 $34.75
Resistance Level $82.85 $40.31
Average True Range (ATR) 2.45 2.05
MACD 0.28 -0.48
Stochastic Oscillator 97.08 35.16

Price Performance

Historical Comparison
IONS
CART

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

About CART Maplebear Inc.

Maplebear (Instacart) is a grocery-focused delivery marketplace that connects national and regional grocers with consumers and couriers, and consumers with their favorite stores. Its app provides on-demand convenience for consumers, allows couriers to earn income, and helps grocers to scale their business through digital channels. The marketplace gathers valuable consumer behavior data, attracting consumer-packaged-goods advertisers that seek to reach consumers at the point of purchase. With approximately 600,000 shoppers and 1,800 retail partners, Instacart delivers to about 98% of households in the United States and Canada.

Share on Social Networks: